Biocon received approval to sell Insulin Glargine in Japan

Posted on:01 Apr 2016 10:19:18
Biocon received approval to sell Insulin Glargine in Japan
01 April 2016 Current Affairs: Biocon Ltd on 28 March 2016 announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan approved its biosimilar Insulin Glargine.The approval for Insulin Glargine was obtained post successful completion of initial development by Biocon and local Phase III Clinical Studies in over 250 Type 1 Diabetes patients by its partner FUJIFILM Pharma Co. Ltd (FFP) in Japan.The product will be available in Japan in 2017 in the form of disposable pen with 3 ml of 100IU Insulin Glargine. At present, it is available in India with the brand name Basalog One.With this launch, the company is also aiming to capture a significant share of the Japanese Glargine market of 144 million US dollars.It is the second largest market outside of North America and Europe and is largely dominated by disposable pens.Biocon Ltd is India's largest and fully-integrated, innovation-led biopharmaceutical company.The Bengaluru-based company serves its customers in over 100 countries. Its products are focused on chronic diseases like autoimmune, diabetes and cancer.It has successfully developed and taken a range of novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogs from 'Lab to Market'.It has a rich pipeline of biosimilars and novel biologics at various stages of development including high potential oral insulin.
Biocon Ltd on 28 March 2016 announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan approved its biosimilar Insulin Glargine.The approval for Insulin Glargine was obtained post successful completion of initial development by Biocon and local Phase III Clinical Studies in over 250 Type 1 Diabetes patients by its partner FUJIFILM Pharma Co. Ltd (FFP) in Japan.The product will be available in Japan in 2017 in the form of disposable pen with 3 ml of 100IU Insulin Glargine. At present, it is available in India with the brand name Basalog One.With this launch, the company is also aiming to capture a significant share of the Japanese Glargine market of 144 million US dollars.It is the second largest market outside of North America and Europe and is largely dominated by disposable pens.Biocon Ltd is India's largest and fully-integrated, innovation-led biopharmaceutical company.The Bengaluru-based company serves its customers in over 100 countries. Its products are focused on chronic diseases like autoimmune, diabetes and cancer.It has successfully developed and taken a range of novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogs from 'Lab to Market'.It has a rich pipeline of biosimilars and novel biologics at various stages of development including high potential oral insulin.

Daily Current Affairs Videos Video Link
20th April 2019 Current Affairs Video
19th April 2019 Current Affairs Video
17th April 2019 Current Affairs Video
16th April 2019 Current Affairs Video
15th April 2019 Current Affairs Video
Watch more Current Affairs Videos

Monthly Current Affairs

Fresherslive telegram Group

Current Affairs Section

Daily Current Affairs Quiz


Subscribe to Current Affairs

Enter your email to get daily current affairs
SUBSCRIBE

Currentt Affairs 2019 April

21 APRIL
NEWS
20 APRIL
NEWS
19 APRIL
NEWS
18 APRIL
NEWS

Currentt Affairs 2019 March

31 MARCH
NEWS
30 MARCH
NEWS
29 MARCH
NEWS
28 MARCH
NEWS

Currentt Affairs 2019 February

28 FEBRUARY
NEWS
27 FEBRUARY
NEWS
26 FEBRUARY
NEWS
25 FEBRUARY
NEWS




×

₹ 250

₹ 1000

Only 14 days left !